Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Eli Lilly's small pop was due to the latest developments in the ... Participants in the 36-week trial experienced a nearly 10 ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Novo Nordisk's CEO said on Wednesday side-effects were not a problem in the trial of its next-generation obesity drug ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Gastrointestinal side effects were merely mild to ... and tirzepatide in the case of Eli Lilly. Waxing bullish about the effects of Novo Nordisk's latest findings on Eli Lilly sentiment was ...

Eli Lilly's small pop was due to the latest developments ... on average. Gastrointestinal side effects were merely mild to moderate, according to the company. This weight loss, and the speed ...